The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study
Open accessAbstract
Background Plasma tau phosphorylated at threonine 217 (p-tau217) and plasma tau phosphorylated at threonine 181 (p-tau181) are associated with Alzheimer's disease tau pathology. We compared the diagnostic value of both biomarkers in cognitively unimpaired participants and patients with a clinical diagnosis of mild cognitive impairment, Alzheimer's disease syndromes, or frontotemporal lobar degeneration (FTLD) syndromes.Methods In this retrospective multicohort diagnostic performance study, we analysed plasma samples, obtained from patients aged 18-99 years old who had been diagnosed with Alzheimer's disease syndromes (Alzheimer's disease dementia, logopenic variant primary progressive aphasia, or posterior cortical atrophy), FTLD syndromes (corticobasal syndrome, progressive supranuclear palsy, behavioural variant frontotemporal dementia, non-fluent variant primary progressive aphasia, or semantic variant primary progressive aphasia), or mild cognitive impairment; the participants were from the University of California San Francisco (UCSF) Memory and Aging Center, San Francisco, CA, USA, and the Advancing Research and Treatment for Frontotemporal Lobar Degeneration Consortium (ARTFL; 17 sites in the USA and two in Canada). Participants from both cohorts were carefully characterised, including assessments of CSF p-tau181, amyloid-PET or tau-PET (or both), and clinical and cognitive evaluations. Plasma p-tau181 and p-tau217 were measured using electrochemiluminescence-based assays, which differed only in the biotinylated antibody epitope specificity. Receiver operating characteristic analyses were used to determine diagnostic accuracy of both plasma markers using clinical diagnosis, neuropathological findings, and amyloid-PET and tau-PET measures as gold standards. Difference between two area under the curve (AUC) analyses were tested with the Delong test.Findings Data were collected from 593 participants (443 from UCSF and 150 from ARTFL, mean age 64 years [SD 13], 294 [50%] women) between July 1 and Nov 30, 2020. Plasma p-tau217 and p-tau181 were correlated (r=0·90, p<0·0001). Both p-tau217 and p-tau181 concentrations were increased in people with Alzheimer's disease syndromes (n=75, mean age 65 years [SD 10]) relative to cognitively unimpaired controls (n=118, mean age 61 years [SD 18]; AUC=0·98 [95% CI 0·95-1·00] for p-tau217, AUC=0·97 [0·94-0·99] for p-tau181; p diff=0·31) and in pathology-confirmed Alzheimer's disease (n=15, mean age 73 years [SD 12]) versus pathologically confirmed FTLD (n=68, mean age 67 years [SD 8]; AUC=0·96 [0·92-1·00] for p-tau217, AUC=0·91 [0·82-1·00] for p-tau181; p diff=0·22). P-tau217 outperformed p-tau181 in differentiating patients with Alzheimer's disease syndromes (n=75) from those with FTLD syndromes (n=274, mean age 67 years [SD 9]; AUC=0·93 [0·91-0·96] for p-tau217, AUC=0·91 [0·88-0·94] for p-tau181; p diff=0·01). P-tau217 was a stronger indicator of amyloid-PET positivity (n=146, AUC=0·91 [0·88-0·94]) than was p-tau181 (n=214, AUC=0·89 [0·86-0·93]; p diff=0·049). Tau-PET binding in the temporal cortex was more strongly associated with p-tau217 than p-tau181 (r=0·80 vs r=0·72; p diff<0·0001, n=230).Interpretation Both p-tau217 and p-tau181 had excellent diagnostic performance for differentiating patients with Alzheimer's disease syndromes from other neurodegenerative disorders. There was some evidence in favour of p-tau217 compared with p-tau181 for differential diagnosis of Alzheimer's disease syndromes versus FTLD syndromes, as an indication of amyloid-PET-positivity, and for stronger correlations with tau-PET signal. Pending replication in independent, diverse, and older cohorts, plasma p-tau217 and p-tau181 could be useful screening tools to identify individuals with underlying amyloid and Alzheimer's disease tau pathology.Funding US National Institutes of Health, State of California Department of Health Services, Rainwater Charitable Foundation, Michael J Fox foundation, Association for Frontotemporal Degeneration, Alzheimer's Association.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, plasma p‐tau217 often shows a superior association with temporal lobe tau load compared to other plasma biomarkers (including other p‐tau species), 13 , 25 , 36”
From Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several recent studies have reported that plasma biomarkers have excellent diagnostic accuracy for AD, with sensitivity or specificity often exceeding 90% (refs. 4–10).”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although total tau and amyloid β concentrations are not sensitive or specific for any of the frontotemporal lobar degeneration proteinopathies, elevated phosphorylated tau concentrations in either CSF or plasma suggest that underlying Alzheimer's disease pathology is likely to be the cause of the frontotemporal dementia clinical syndrome.49,55,56”
From Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations (2022) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Notably, p-tau217 exhibits larger-fold changes compared with p-tau181 and p-tau231,10 often achieving high discrimination, with areas under the curve (AUC) exceeding 90%.19,23”
From Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology (2024) · cites this paper as [23]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although total tau and amyloid β concentrations are not sensitive or specific for any of the frontotemporal lobar degeneration proteinopathies, elevated phosphorylated tau concentrations in either CSF or plasma suggest that underlying Alzheimer's disease pathology is likely to be the cause of the frontotemporal dementia clinical syndrome.49,55,56”
From Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations (2022) · cites this paper as [56]
Experimental — accuracy not yet measured
In the citing paper
“Like NfL (neurofilament light chain), plasma tau has emerged as a marker of neuronal distress. It appears in several different neurodegenerative diseases, including importantly even preclinical AD patients (76–85).”
From All the Tau We Cannot See (2023) · cites this paper as [85]
In the citing paper
“It appears to be more specific for AD pathology, at least compared to frontotemporal dementia and chronic traumatic encephalopathy (85, 91, 92), but it is increased in prion disease (83).”
From All the Tau We Cannot See (2023) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Self-citationDiagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Self-citationMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
Appelhof, B., Bakker, C., den IJssel, J. C. L. V. D., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,774
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,434
Self-citation
Cited by
Sorted by citations
Items 101–200 of 614
Du, L., Langhough, R. E., Wilson, R. E., Reyes, R. E. R., Hermann, B. P., Jonaitis, E. M., Betthauser, T. J., Chin, N. A., Christian, B., Chaby, L., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14100 · Cited by 46
Self-citationYakoub, Y., González‐Ortiz, F., Ashton, N. J., Déry, C., Strikwerda‐Brown, C., St‐Onge, F., Ourry, V., Schöll, M., Geddes, M. R., Ducharme, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14537 · Cited by 62
Self-citationThe night’s watch: Exploring how sleep protects against neurodegeneration
Parhizkar, S., & Holtzman, D. M. (2025) · Neuron · doi:10.1016/j.neuron.2025.02.004 · Cited by 54
Malpetti, M., Joie, R. L., & Rabinovici, G. D. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263694 · Cited by 45
Self-citationSaloner, R., VandeVrede, L. A., Asken, B. M., Paolillo, E. W., Gontrum, E. Q., Wolf, A. A., Lario‐Lago, A., Milà‐Alomà, M., Triana‐Baltzer, G., Kolb, H. C., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13454 · Cited by 49
Self-citationA head‐to‐head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic
Anastasi, F., Fernández‐Lebrero, A., Ashton, N. J., Ortiz‐Romero, P., Torres‐Torronteras, J., González‐Escalante, A., Milà‐Alomà, M., Contador, J., García‐Escobar, G., Manero-Borràs, R. M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14609 · Cited by 49
Self-citationAsken, B. M., Tanner, J. A., VandeVrede, L., Mantyh, W. G., Casaletto, K. B., Staffaroni, A. M., La Joie, R., Iaccarino, L., Soleimani-Meigooni, D., Rojas, J. C., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200678 · Cited by 40
Self-citationVandeVrede, L. A., Joie, R. L., Thijssen, E. H., Asken, B. M., Vento, S. A., Tsuei, T., Baker, S. L., Cobigo, Y., Fonseca, C. S., Heuer, H. W., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.0488 · Cited by 45
Self-citationVacchiano, V., Mastrangelo, A., Zenesini, C., Baiardi, S., Avoni, P., Polischi, B., Capellari, S., Salvi, F., Liguori, R., & Parchi, P. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-330709 · Cited by 49
Schöll, M., Vrillon, A., Ikeuchi, T., Quevenco, F. C., Iaccarino, L., Vasileva-Metodiev, S. Z., Burnham, S. C., Hendrix, J. A., Epelbaum, S., Zetterberg, H., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100056 · Cited by 48
Self-citationWang, S., Deng, R., Chen, Z., Huang, L., Song, Y., Yuan, D., Li, Y., Liu, H., Yang, F., Fan, B., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c09311 · Cited by 44
Fluid biomarkers for the diagnosis of neurodegenerative diseases
Luebke, M., Parulekar, M. S., & Thomas, F. P. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100062 · Cited by 42
Plasma biomarkers for prediction of Alzheimer’s disease neuropathologic change
Bermudez, C. L., Graff‐Radford, J., Syrjanen, J. A., Stricker, N. H., Algeciras‐Schimnich, A., Kouri, N., Kremers, W. K., Petersen, R. C., Jack, C. R., Knopman, D. S., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02594-w · Cited by 43
Li, M., Zeng, Y., Huang, Z., Zhang, L., & Liu, Y. (2023) · Biosensors · doi:10.3390/bios13080758 · Cited by 42
Tau as a serum biomarker of delirium after major cardiac surgery: a single centre case-control study
McKay, T. B., Qu, J. Z., Liang, F., Mueller, A., Wiener-Kronish, J. P., Xie, Z., & Akeju, O. (2022) · British Journal of Anaesthesia · doi:10.1016/j.bja.2022.04.002 · Cited by 41
BACE1 Inhibitors for Alzheimer’s Disease: Current Challenges and Future Perspectives
Coimbra, J. R. M., Resende, R., Custódio, J. B. A., Salvador, J. A. R., & Santos, A. E. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240146 · Cited by 43
Hyman, B. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-023749 · Cited by 39
Zabala-Findlay, A., Penny, L. K., Lofthouse, R. A., Porter, A. J., Palliyil, S., Harrington, C. R., Wischik, C. M., & Arastoo, M. (2023) · Cells · doi:10.3390/cells12081184 · Cited by 40
Dark, H. E., Duggan, M. R., & Walker, K. A. (2024) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acae019 · Cited by 42
Hu, Y., Cho, M., Sachdev, P., Dage, J., Hendrix, S., Hansson, O., Bateman, R. J., & Hampel, H. (2024) · Med · doi:10.1016/j.medj.2024.08.004 · Cited by 42
Self-citationUchida, K. (2022) · Cells · doi:10.3390/cells11050919 · Cited by 41
Hirota, Y., Sakakibara, Y., Ibaraki, K., Takei, K., Iijima, K., & Sekiya, M. (2022) · Brain Communications · doi:10.1093/braincomms/fcac286 · Cited by 41
Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00741-9 · Cited by 42
Self-citationInfluence of medical conditions on the diagnostic accuracy of plasma p‐tau217 and p‐tau217/Aβ42
Olvera‐Rojas, M., Sewell, K. R., Karikari, T. K., Huang, H., Oberlin, L. E., Zeng, X., Morris, J. K., Collins, A. M., Drake, J. A., Sutton, B. P., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14430 · Cited by 39
Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer’s disease
Guo, T., Li, A., Sun, P., He, Z., Cai, Y., Lan, G., Liu, L., Li, J., Yang, J., Zhu, Y., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00750-8 · Cited by 41
Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data
Karlsson, L., Vogel, J., Arvidsson, I., Åström, K., Strandberg, O., Seidlitz, J., Bethlehem, R. A. I., Stomrud, E., Ossenkoppele, R., Ashton, N. J., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.14600 · Cited by 43
Self-citationPlasma phosphorylated tau181 predicts cognitive and functional decline
Tropea, T. F., Waligórska, T., Xie, S. X., Nasrallah, I. M., Cousins, K. A. Q., Trojanowski, J. Q., Grossman, M., Irwin, D. J., Weintraub, D. A., Lee, E. B., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51695 · Cited by 39
A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings
Brum, W. S., Cullen, N. C., Therriault, J., Janelidze, S., Rahmouni, N., Stevenson, J., Servaes, S., Benedet, A. L., Zimmer, E. R., Stomrud, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46603-2 · Cited by 41
Self-citationBadhwar, A., Hirschberg, Y., Valle‐Tamayo, N., Iulita, M. F., Udeh‐Momoh, C. T., Matton, A., Tarawneh, R. M., Rissman, R. A., Ledreux, A., Winston, C. N., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13823 · Cited by 34
Unraveling Alzheimer’s disease: insights from single-cell sequencing and spatial transcriptomic
He, Y., Lu, W., Zhou, X. M., Mu, J., & Shen, W. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1515981 · Cited by 40
Novel blood‐based proteomic signatures across multiple neurodegenerative diseases
Durcan, R., Heslegrave, A., Swann, P., Goddard, J., Chouliaras, L., Murley, A. G., Savulich, G., Bevan-Jones, W. R., Swann, O., Ashton, N. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70116 · Cited by 36
Self-citationPlasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease
Cousins, K. A. Q., Irwin, D. J., Chen‐Plotkin, A. S., Shaw, L. M. J., Arezoumandan, S., Lee, E. B., Wolk, D. A., Weintraub, D. A., Spindler, M., Deik, A., et al. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51768 · Cited by 38
Honig, L. S., Kang, M. S., Lee, A., Reyes‐Dumeyer, D., Piriz, A. L., Soriano, B., Franco, Y., Coronado, Z. D., Recio, P., Mejía, D. R., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.8214 · Cited by 33
Self-citationZhao, K., Chen, P., Alexander‐Bloch, A. F., Wei, Y., Dyrba, M., Yang, F., Kang, X., Wang, D., Fan, D., Shan, Y., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102276 · Cited by 38
Sanchez, E., Coughlan, G., Wilkinson, T., Ramirez, J., Mirza, S. S., Baril, A., Dilliott, A. A., Frank, A. R., Lang, A. E., Hassan, A. A., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213438 · Cited by 37
Self-citationCousins, K. A. Q., Korecka, M., Wan, Y., Vulaj, A., Brown, C. D., Tropea, T. F., Lee, E. B., Tosun, D., Landau, S. M., Okonkwo, O. C., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70469 · Cited by 35
Jarek, D. J., Mizerka, H., Nuszkiewicz, J., & Szewczyk‐Golec, K. (2024) · Biomedicines · doi:10.3390/biomedicines12040786 · Cited by 37
Tau; One Protein, So Many Diseases
Tabeshmehr, P., & Eftekharpour, E. (2023) · Biology · doi:10.3390/biology12020244 · Cited by 33
Vila‐Castelar, C., Chen, Y., Langella, S., Lopera, F. J., Zetterberg, H., Hansson, O., Dage, J. L., Janelidzde, S., Su, Y., Chen, K., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13314 · Cited by 35
Self-citationP-tau217 in Alzheimer’s disease
Telser, J., Risch, L., Saely, C. H., Grossmann, K., & Werner, P. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.03.018 · Cited by 32
Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease
Pagonabarraga, J., Pérez‐González, R., Bejr‐Kasem, H., Marín‐Lahoz, J., Horta‐Barba, A., Martínez‐Horta, S., Aracil‐Bolaños, I., Sampedro, F., Campolongo, A., Rivas, E. I., et al. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.05.020 · Cited by 33
Dyer, A. H., Dolphin, H., O’Connor, A., Morrison, L., Sedgwick, G., Young, C., Killeen, E., Gallagher, C., McFeely, A., Connolly, E., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01555-z · Cited by 39
Álvarez-Sánchez, L., Peña-Bautista, C., Ferré-González, L., Balaguer, A., Baquero, M., Casanova-Estruch, B., & Cháfer-Pericás, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021226 · Cited by 32
Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease
Brickman, A. M., Manly, J. J., Honig, L. S., Sanchez, D. L., Reyes‐Dumeyer, D., Lantigua, R., Vonsattel, J. P., Teich, A. F., Kang, M. S., Dage, J. L., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51529 · Cited by 32
Self-citationJiao, B., Zhang, S., Bei, Y., Bu, G., Li, Y., Zhu, Y., Yang, Q., Xu, T., Zhou, L., Liu, Q., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13053 · Cited by 31
Giacomucci, G., Mazzeo, S., Crucitti, C., Ingannato, A., Bagnoli, S., Padiglioni, S., Galdo, G., Emiliani, F., Frigerio, D., Moschini, V., et al. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.120805 · Cited by 31
Application of biomarker-derived fluorescent probes for the detection of Alzheimer's disease
Ding, H., Li, Z., Luo, K., Gong, Q., & Tian, X. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117369 · Cited by 30
A critical appraisal of blood-based biomarkers for Alzheimer’s disease
Lista, S., Mapstone, M. E., Caraci, F., Emanuele, E., López‐Ortiz, S., Martín-Hernández, J., Triaca, V., Imbimbo, C., Gabelle, A., Mielke, M. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102290 · Cited by 30
Benussi, A., Huber, H., Tan, K., Cantoni, V., Rivolta, J., Cotelli, M. S., Benedet, A. L., Blennow, K., Zetterberg, H., Ashton, N. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14482 · Cited by 33
Self-citationPhospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
Meyer, S. D., Vanbrabant, J., Schaeverbeke, J. M., Reinartz, M., Luckett, E. S., Dupont, P. J., Laere, K. V., Stoops, E., Vanmechelen, E., Poesen, K., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51553 · Cited by 32
Zheng, H., Wu, Z., Mielke, M. M., Murray, A. M., & Ryan, J. L. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.142 · Cited by 29
Meijer, L., Chrétien, E., & Ravel, D. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240078 · Cited by 30
Blood based biomarkers for movement disorders
Morris, H. R. (2022) · Acta Neurologica Scandinavica · doi:10.1111/ane.13700 · Cited by 29
Retinal Alterations Predict Early Prodromal Signs of Neurodegenerative Disease
Casciano, F., Zauli, E., Celeghini, C., Caruso, L., Gonelli, A., Zauli, G., & Pignatelli, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031689 · Cited by 34
Delva, A., Pelletier, A., Somerville, E. N., Montplaisir, J. Y., Gagnon, J., Kollmorgen, G., Kam‐Thong, T., Kustermann, T., Machado, V., Gan‐Or, Z., et al. (2025) · Brain · doi:10.1093/brain/awaf003 · Cited by 33
Bandara, E. M. S., Asih, P. R., Pedrini, S., Hone, E., Fernando, W. M. A. D. B., & Martins, R. N. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05219-3 · Cited by 37
Predictive blood biomarkers and brain changes associated with age-related cognitive decline
Saunders, T. S., Pozzolo, F. E., Heslegrave, A., King, D., McGeachan, R. I., Spires-Jones, M. P., Harris, S. E., Ritchie, C. W., Terrera, G. M., Deary, I. J., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad113 · Cited by 29
Self-citationIncrease of ALCAM and VCAM-1 in the plasma predicts the Alzheimer’s disease
Chen, J., Dai, A., Tang, H., Lu, C., Liu, H., Hou, T., Lu, Z., Kong, N., Peng, X.-Y., Lin, K.-X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1097409 · Cited by 28
Tsoy, E., Joie, R. L., VandeVrede, L. A., Rojas, J. C., Yballa, C., Chan, B., Lago, A. L., Rodriguez, A., Goode, C. A., Erlhoff, S. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13686 · Cited by 28
Self-citationIdentification of late-stage tau accumulation using plasma phospho-tau217
Woo, M. S., Therriault, J., Jonaitis, E. M., Wilson, R. E., Langhough, R. E., Rahmouni, N., Benedet, A. L., Ashton, N. J., Tissot, C., Lantero‐Rodriguez, J., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105413 · Cited by 34
Self-citationSelma‐González, J., Rubio‐Guerra, S., Castro, J. G., Vera-Campuzano, E., Sala, I., Sánchez‐Saudinós, M. B., Zhu, N., Arranz, J., Arriola‐Infante, J. E., Rodríguez‐Baz, Í., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213769 · Cited by 28
Self-citationXiao, Z., Wu, W., Ma, X., Liang, X., Lu, J., Zheng, L., Ding, S., Lei, Q., Luo, J., Chen, K., et al. (2022) · Clinical Chemistry · doi:10.1093/clinchem/hvac149 · Cited by 28
Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints
Lu, J., Ma, X., Zhang, H., Xiao, Z., Li, M., Wu, J., Ju, Z., Chen, L., Zheng, L., Ge, J., et al. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00365-x · Cited by 28
Muir, R. T., Ismail, Z., Black, S. E., & Smith, E. E. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13510 · Cited by 27
Comorbidities confound Alzheimer’s blood tests
Schindler, S. E., & Karikari, T. K. (2022) · Nature Medicine · doi:10.1038/s41591-022-01875-3 · Cited by 27
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Bali, D., Hansson, O., & Janelidze, S. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01391-1 · Cited by 31
Self-citationSattarov, R., Havers, M., Orbjörn, C., Stomrud, E., Janelidze, S., Laurell, T., & Mattsson, N. (2024) · Scientific Reports · doi:10.1038/s41598-024-75406-0 · Cited by 29
Wojdała, A. L., Vanbrabant, J., Bayoumy, S., Antwi‐Berko, D., Bastard, N. L., van der Flier, W. M., Jeromin, A., Lambrechts, C., Loo, M. V., Vandijck, M. L. J., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01630-5 · Cited by 33
Self-citationWojdała, A. L., Bellomo, G., Gaetani, L., Teunissen, C. E., Parnetti, L., & Chiasserini, D. (2025) · Nature Communications · doi:10.1038/s41467-024-54878-8 · Cited by 30
Self-citationAntonioni, A., Raho, E. M., Lorenzo, F. D., Manzoli, L., Flacco, M. E., & Koch, G. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12996-3 · Cited by 34
Kubota, M., Bun, S., Takahata, K., Kurose, S., Momota, Y., Iwabuchi, Y., Tezuka, T., Tabuchi, H., Seki, M., Yamamoto, Y., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01778-8 · Cited by 34
Selective Detection of Misfolded Tau From Postmortem Alzheimer’s Disease Brains
Wu, L., Wang, Z., Lad, S., Gilyazova, N., Dougharty, D. T., Marcus, M., Henderson, F. E., Ray, W. K., Siedlak, S. L., Li, J., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.945875 · Cited by 28
Huang, Z., Li, M., Zhang, L., & Liu, Y. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1029428 · Cited by 27
Associations of Blood and Cerebrospinal Fluid Aβ and tau Levels with Renal Function
Sun, H., Yao, X., Li, L., Jin, W., Bai, Y., Zeng, G., Shi, A., Liang, J., Zhu, L., Liu, Y.-H., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03420-w · Cited by 27
Krawczuk, D., Kulczyńska‐Przybik, A., & Mroczko, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158132 · Cited by 26
Biomarkers in frontotemporal dementia: Current landscape and future directions
Gifford, A., Praschan, N. C., Newhouse, A. L., & Chemali, Z. N. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100065 · Cited by 29
Comparison of cerebrospinal fluid, plasma and neuroimaging biomarker utility in Alzheimer’s disease
Meeker, K. L., Luckett, P. H., Barthélemy, N. R., Hobbs, D. A., Chen, C. D., Bollinger, J., Ovod, V., Flores, S. E., Keefe, S., Henson, R. L., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae081 · Cited by 30
Temporal Dynamics and Biological Variability of Alzheimer Biomarkers
Yun, J., Shin, D., Lee, E. H., Kim, J. P., Ham, H., Gu, Y., Chun, M. Y., Kang, S. H., Kim, Y. J., Na, D. L., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2024.5263 · Cited by 32
Self-citationTau proteins in blood as biomarkers of Alzheimer’s disease and other proteinopathies
Verde, F. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02471-y · Cited by 26
Tau PET imaging in progressive supranuclear palsy: a systematic review and meta-analysis
Jin, J., Su, D., Zhang, J., Li, X., & Feng, T. (2023) · Journal of Neurology · doi:10.1007/s00415-022-11556-3 · Cited by 26
Differential roles of Alzheimer's disease plasma biomarkers in stepwise biomarker‐guided diagnostics
Jang, H., Shin, D., Yoo, H., Zetterberg, H., Blennow, K., González‐Ortiz, F., Ashton, N. J., Day, T. A., Lee, E. H., Yun, J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14526 · Cited by 26
Self-citationBlood Biomarkers for the Diagnosis of Neurodegenerative Dementia: A Systematic Review
Santos, F., Cabreira, V., Rocha, S., & Massano, J. (2023) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887221141651 · Cited by 24
Genetic risk scores enhance the diagnostic value of plasma biomarkers of brain amyloidosis
Ramanan, V. K., Gebre, R. K., Graff-Radford, J., Hofrenning, E., Algeciras-Schimnich, A., Figdore, D. J., Lowe, V. J., Mielke, M. M., Knopman, D. S., Ross, O. A., et al. (2023) · Brain · doi:10.1093/brain/awad196 · Cited by 24
Matthews, D. C., Kinney, J. W., Ritter, A. R., Andrews, R. D., Strom, E. N. T., Lukic, A. S., Koenig, L. N., Revta, C., Fillit, H. M., Zhong, K., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12490 · Cited by 25
Present and Future of Blood-Based Biomarkers of Alzheimer’s Disease: Beyond the Classics
Grigoli, M. M., Pelegrini, L. N. D. C., Whelan, R., & Cominetti, M. R. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148812 · Cited by 22
Álvarez‐Sánchez, L., Peña‐Bautista, C., Baquero, M., & Cháfer‐Pericás, C. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215093 · Cited by 25
Plasma Alzheimer's biomarkers and brain amyloid in Hispanic and non‐Hispanic older adults
Asken, B. M., Wang, W., McFarland, K. N., Arias, F., Fiala, J. A., Vélez-Uribe, I., Mayrand, R. P., Sawada, L. O., Freytes, C. Y., Adeyosoye, M., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13456 · Cited by 22
Dilcher, R., Wall, S., Groß, M., Katzdobler, S., Wagemann, O., Palleis, C., Weidinger, E., Fietzek, U. M., Bernhardt, A., Kurz, C., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14185 · Cited by 23
Plasma p‐tau217 concordance with amyloid PET among ethnically diverse older adults
Asken, B. M., DeSimone, J. C., Wang, W., McFarland, K. N., Arias, F., Levy, S.-A. T., Fiala, J. A., Vélez-Uribe, I., Mayrand, R. P., Sawada, L. O., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12617 · Cited by 23
Wang, J., Lu, X., & He, Y. (2025) · Biosensors · doi:10.3390/bios15020085 · Cited by 24
McCarter, S. J., Lesnick, T. G., Lowe, V. J., Rabinstein, A. A., Przybelski, S. A., Algeciras‐Schimnich, A., Ramanan, V. K., Jack, C. R., Petersen, R. C., Knopman, D. S., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220158 · Cited by 22
Self-citationMa, Y., Brettschneider, J. A., & Collingwood, J. F. (2022) · Biomedicines · doi:10.3390/biomedicines10071713 · Cited by 24
Parvizi, T., König, T., Wurm, R., Silvaieh, S., Altmann, P., Klotz, S., Rommer, P. S., Furtner, J., Regelsberger, G., Lehrner, J., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.887498 · Cited by 25
Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy
Huang, S., Chen, S., Cui, M., Zhao, M., Shen, X., Guo, Y., Zhang, Y.-R., Zhang, W., Wang, H.-F., Huang, Y., et al. (2023) · Movement Disorders · doi:10.1002/mds.29339 · Cited by 23
Jones, K. T., Gallen, C. L., Ostrand, A. E., Rojas, J. C., Wais, P. E., Rini, J. F., Chan, B., Lago, A. L., Boxer, A. L., Zhao, M., et al. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.04.005 · Cited by 23
Self-citationLecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease
Park, J., Simpson, C., & Patel, K. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231218253 · Cited by 25
Sarto, J., Esteller, D., Guillén, N., Falgàs, N., Borrego‐Écija, S., Massons, M., Fernández‐Villullas, G., González, Y., Tort‐Merino, A., Bosch, B., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12897-5 · Cited by 23
Site-Specific Phospho-Tau Aggregation-Based Biomarker Discovery for AD Diagnosis and Differentiation
Wu, L., Gilyazova, N., Ervin, J. F., Wang, S. J., & Xu, B. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00342 · Cited by 20
Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease
Cousins, K. A. Q., Phillips, J. S., Das, S. R., O’Brien, K. S., Tropea, T. F., Chen‐Plotkin, A. S., Shaw, L. M. J., Nasrallah, I. M., Mechanic-Hamilton, D. J., McMillan, C. T., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13777 · Cited by 21
Tau burden is best captured by magnitude and extent: Tau‐MaX as a measure of global tau
Brown, C., Das, S. R., Cousins, K. A. Q., Tropea, T. F., Plotkin, A., Detre, J. A., Yushkevich, P. A., McMillan, C. T., Lee, E. B., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70346 · Cited by 20
Metadata
- Authors
- Thijssen, E. H., La Joie, R., Strom, A., Fonseca, C., Iaccarino, L., Wolf, A., Spina, S., Allen, I. E., Cobigo, Y., Heuer, H., VandeVrede, L., Proctor, N. K., Lago, A. L., Baker, S., Sivasankaran, R., Kieloch, A., Kinhikar, A., Yu, L., Valentin, M.-A., Jeromin, A., Zetterberg, H., Hansson, O., Mattsson-Carlgren, N., Graham, D., Blennow, K., Kramer, J. H., Grinberg, L. T., Seeley, W. W., Rosen, H., Boeve, B. F., Miller, B. L., Teunissen, C. E., Rabinovici, G. D., Rojas, J. C., Dage, J. L., & Boxer, A. L.
- Affiliations
- University of California, San Francisco (US)
- Eli Lilly (United States) (US)
- Lawrence Berkeley National Laboratory (US)
- Quanterix (United States) (US)
- Sahlgrenska University Hospital (SE)
- Lund University (SE)
- Biogen (United States) (US)
- Mayo Clinic (US)
- Amsterdam Neuroscience (NL)
- Corresponding author
- Boxer, Adam L
- ORCID
- Thijssen, Elisabeth H
- Strom, Amelia
- Fonseca, Corrina
- Iaccarino, Leonardo
- Wolf, Amy
- Spina, Salvatore
- Allen, Isabel E
- Cobigo, Yann
- Heuer, Hilary
- VandeVrede, Lawren
- Proctor, Nicholas K
- Lago, Argentina Lario
- Baker, Suzanne
- Sivasankaran, Rajeev
- Kinhikar, Arvind
- Yu, Lili
- Zetterberg, Henrik
- Hansson, Oskar
- Graham, Danielle
- Blennow, Kaj
- Kramer, Joel H
- Grinberg, Lea T
- Seeley, William W
- Rosen, Howard
- Boeve, Bradley F
- Miller, Bruce L
- Teunissen, Charlotte E
- Rabinovici, Gil D
- Rojas, Julio C
- Dage, Jeffrey L
- Boxer, Adam L
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 20
- Issue
- 9
- Pages
- 739-752
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC8711249
- OpenAlex
- W3194829575
- Cited by
- 607
- References
- 40
- Citations by year
- 2026: 127 · 2025: 161 · 2024: 119 · 2023: 101 · 2022: 87 · 2021: 11
- FWCI
- 57.94
- Type
- journal article
- Language
- en
- Update notices
- erratum (2021-10-01)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Alzheimer's Association (AARF-16\u2013443577, 443577)
- National Center for Advancing Translational Sciences (LEFFTDS U01 AG045390)
- National Institute of Neurological Disorders and Stroke (U54NS092089)
- National Institute on Aging
- American College of Radiology
- Association for Frontotemporal Degeneration
- Rainwater Charitable Foundation
- NIH (R01 AG045611, U24AG21886, K24AG053435, R01AG038791, P50AG016574, K99AG065501, U19AG063911, P50AG023501, P01AG019724)
- Vetenskapsrådet (2018\u201302532, 02532)
- Little Family Foundation
- European Research Council (681712)
- Michael J Fox Foundation for Parkinson's Research
- Alzheimer's Drug Discovery Foundation (201809\u20132016862, 2016862, 201809)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- Alzheimer's disease, frontotemporal lobar degeneration, plasma biomarkers, diagnostic accuracy, mild cognitive impairment, tau PET, amyloid PET, primary progressive aphasia, corticobasal syndrome, progressive supranuclear palsy, behavioral variant frontotemporal dementia, posterior cortical atrophy, logopenic variant primary progressive aphasia, semantic dementia, electrochemiluminescence assay
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Phosphorylation, Predictive Value of Tests, Retrospective Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography, Frontotemporal Lobar Degeneration, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
